BioInvent International
Edla Lindberg began working as a QC Engineer at BioInvent International AB in October 2021. Before that, they worked at Region Skåne as an Assistant Healthcare in Lab Analysis from June 2016 to November 2022.
Edla Lindberg pursued a Bachelor's degree in Biomedical Laboratory Science at Malmö University from 2018 to 2021. Prior to that, they attended The Faculty of Engineering at Lund University in 2013, where they studied Biotechnology. The duration of their enrollment at Lund University is not specified.
BioInvent International
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l/ll trials for the treatment of hematological cancer and solid tumors, respectively.